$TNYA

Tingley Whittemore sold $5K of TNYA

Tingley Whittemore (Chief Medical Officer) sold 7,424 shares of Tenaya Therapeutics, Inc. (TNYA) at $0.71 across 4 trades on 2026-08-17.

Original reporting
SEC EDGAR · Tingley Whittemore
Published Aug 18, 2026, 12:49 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 1:05 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TNYA
Neutral
medium confidence
Mentioned
$TNYA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TNYANeutralLow
01

Why it matters

An insider open-market sale can slightly pressure sentiment, but without accompanying guidance, trial results, financing, or regulatory updates, it is unlikely to drive a sustained repricing.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the disclosure alone is not a fundamental catalyst.

03

What to watch

The article does not state whether the sale was part of a 10b5-1 plan (it says no), but it also provides no context on prior grants, option exercises, or total insider ownership changes beyond the post-trade share count.

Relevance 3/10Novelty 2/10Timing: filed 2026-08-17 after-hours; transaction dated 2026-08-17

Background

The article is an SEC Form 4 insider transaction disclosure for Tenaya Therapeutics, Inc.

Company-level read

Ticker impact

$TNYANeutralMedium confidence
Context

Tenaya Therapeutics insider Form 4 shows CMO Tingley Whittemore sold 7,424 shares at $0.7098 on 2026-08-17.

Expected impact

Likely limited, short-lived sentiment impact; watch for follow-on selling or other disclosures.

Evidence & confidence

This is a routine Form 4 transaction with small dollar value and no 10b5-1 plan stated, but it is not accompanied by new operating or regulatory information.

Market effects

No clear sector read-through from a single insider sale at a small biotech.

None indicated.

None indicated.

Counterpoint

The sale may be unrelated to company outlook (taxes, diversification, or routine compensation), so it may not signal negative fundamentals.

Key entities

  • Tenaya Therapeutics, Inc.

    Subject of the Form 4 insider sale by its Chief Medical Officer.

  • Tingley Whittemore

    Chief Medical Officer who sold 7,424 shares at $0.7098 on 2026-08-17.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TNYAMed

Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301

Tenaya Therapeutics (NASDAQ:TNYA) said it plans Q4 updates for gene therapy TN-401 in PKP2-associated ARVC, with early data showing ~60% to 67% PVC reductions across patients (up to 52 weeks). It also reported Phase 1 results for TN-301 (72 patients) and Phase 2-enabling work. Tenaya had ~$78M cash and a $10M upfront Alnylam deal.

$TNYAMed

Tenaya Therapeutics, Inc. (TNYA): Results of Operations and Financial Condition

Tenaya Therapeutics, Inc. (TNYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tnya-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements

$TNYAMedAI 9/10

Tenaya's TN-201 Gene Therapy Shows Sustained Cardiac Improvements In MYBPC3-Associated HCM

Tenaya Therapeutics reported interim MyPEAK-1 Phase 1b/2 data for TN-201, an investigational gene therapy for MYBPC3-associated hypertrophic cardiomyopathy. As of a May 2026 cutoff, six evaluable patients showed improvements in echocardiographic hypertrophy and symptom measures; three improved exercise capacity. Company said benefits were sustained up to two years in Cohort 1 and earlier in Cohort 2. PRIME and FDA rare disease processes apply.

$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $6.1M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 246,568 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $24.85 ($24.69–$24.87, $6.13M total) across 3 trades over 2026-08-13 to 2026-08-17. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Divisadero Street Capital, LLC (10% owner), Divisadero Street Partners, L.P. (10% owner) and Zolezzi William (10% owner).